comprehensive -WSS

comprehensive

author：entertainment 2025-09-08 19:10:39 - browse：63

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Male and female sex labels in research insufficient, scientists say

WSS

Amid AI frenzy, a top HHS official's quest to create safeguards

Readout Newsletter: Bristol, Sangamo, Gilead, and more

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Study links childhood stress with decline in older age

How I helped Pfizer think through the ethics of Viagra

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

hotspot

comprehensive

knowledge

The high cost of giving birth even with insurance

The cancer stories no one wants to hear

Virginia high school admissions case could be legal follow

EPA limits use of carcinogenic gas for sterilizing medical devices

The cancer drug shortage isn’t new — and neither are the solutions

A controversial new treatment promises to make little people taller

DIEP, the 'gold standard' of breast reconstruction, is under threat

Pushing for an NIH office for post

Walensky prepares to leave CDC — and Congress — behind

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

knowledge

WuXi out of biotech trade group, U.S. and China relations to blame

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Amid AI frenzy, a top HHS official's quest to create safeguards

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Wikipedia

focus

knowledge

focus